FLOW CYTOMETRY SHARED RESOURCE The Flow Cytometry Shared Resource provides state-of-the-art cell sorting and analysis capability to the members of the Kimmel Cancer Center at Thomas Jefferson University. This shared resource is located in a dedicated laboratory space of about 600 sq ft on the 6th floor of the Bluemle Life Sciences Building, centrally positioned on the Thomas Jefferson University campus. The Flow Cytometry Shared Resource is equiped with one Cytomation MoFlo cell high-speed sorter, one Coutler EPICS Elite flow cytometer capable of sorting, one Coulter XL-MCL automated analytical cytometer, one FACS Calibur Benchtop Analyzer, one FACScan Benchtop Analyzer, two Celeron 400 workstations, one Nikon fluorescence microscope, a 30 cu ft 4?C refrigerator, and a 10 cu ft -20?C freezer. All units are maintained and managed by a dedicated manager/operator. The most commonly used applications are for surface phenotyping and sorting, detection of intracellular cytokines at the single cell level in mixed populations, single cell real time analysis of Ca2* mobilization kinetics, studies of apoptosis, cell cycle analysis, and sorting of viable cells in specific stages of the cell cycle. This shared resource allows experimental and data analysis to be performed in a timely manner and with high sensitivity and accuracy. Peer-review, funded cancer center investigators receive priority for the use of this shared resource. Based on increased capabilities for new services, the steady increase in the use of this resource by cancer center members and the recruitment of new investigators, we project that shared resource usage will increase significantly in the near future. In summary, this shared resource plays a critical role in assisting cancer center investigators as they conduct research into the biology and treatment of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA056036-10
Application #
7923894
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-06-01
Budget End
2010-05-31
Support Year
10
Fiscal Year
2009
Total Cost
$102,175
Indirect Cost
Name
Thomas Jefferson University
Department
Type
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Meyer, Sara E; Muench, David E; Rogers, Andrew M et al. (2018) miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. J Exp Med 215:2115-2136
Mazina, Olga M; Mazin, Alexander V (2018) Reconstituting the 4-Strand DNA Strand Exchange. Methods Enzymol 600:285-305
Magee, Michael S; Abraham, Tara S; Baybutt, Trevor R et al. (2018) Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. Cancer Immunol Res 6:509-516
Chervoneva, Inna; Freydin, Boris; Hyslop, Terry et al. (2018) Modeling qRT-PCR dynamics with application to cancer biomarker quantification. Stat Methods Med Res 27:2581-2595
Capparelli, Claudia; Purwin, Timothy J; Heilman, Shea A et al. (2018) ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Res 78:5680-5693
Nevler, Avinoam; Muller, Alexander J; Cozzitorto, Joseph A et al. (2018) A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. J Am Coll Surg 226:596-603
Peng, Weidan; Furuuchi, Narumi; Aslanukova, Ludmila et al. (2018) Elevated HuR in Pancreas Promotes a Pancreatitis-Like Inflammatory Microenvironment That Facilitates Tumor Development. Mol Cell Biol 38:
Waldman, Scott A; Camilleri, Michael (2018) Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. Gut 67:1543-1552
Sullivan-Reed, Katherine; Bolton-Gillespie, Elisabeth; Dasgupta, Yashodhara et al. (2018) Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. Cell Rep 23:3127-3136
Lu, Huimin; Bowler, Nicholas; Harshyne, Larry A et al. (2018) Exosomal ?v?6 integrin is required for monocyte M2 polarization in prostate cancer. Matrix Biol 70:20-35

Showing the most recent 10 out of 807 publications